The accessibility of data on environmental risk assessment of pharmaceuticals - are environmental risk assessments information on emissions with respect to international and European environmental information law?

Clicks: 413
ID: 75233
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #9 of 111 articles by views in regulatory toxicology and pharmacology : rtp

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In the pharmaceutical sector, the right of access to environmental information is in most cases not feasible as the authorisation holders refer to commercially/industrial confidential information (CCI). However, CCI can not refuse access to environmental risk assessments (ERAs) if ERAs are to be classified as information on emissions. Pharmaceuticals inevitably enter the environment as a consequence of their intended use. This release is calculated in the ERA as predicted environmental concentration when a pharmaceutical is approved. The release of pharmaceuticals into the environment falls consequently under the term 'emissions into the environment'. In addition, the ERAs assessing the risk of this release are to be classified as 'information on emissions into the environment'. Therefore, the practiced secrecy of ERAs of pharmaceuticals and their official assessment reports is incompatible with Art. 4 Aarhus Convention, and the European and national implementing provisions for this article, which require access to such environmental information on emissions for everyone, irrespective of whether they concern CCI. With this legal disclosure obligation of ERAs, there is an enforceable right of access for everyone, which shows the necessity for establishing a publicly accessible database based on active pharmaceutical ingredients with substantiated information on the ERAs.
Reference Key
oelkers2019theregulatory Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Oelkers, Kim;
Journal regulatory toxicology and pharmacology : rtp
Year 2019
DOI
S0273-2300(19)30335-6
URL
Keywords
pharmaceuticals emission environmental risk assessment aarhus convention access to environmental information

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.